Major Depressive Disorder (MDD) Treatment Market: Trends, Share, Size, Growth, Opportunity, and Forecast 2022-2028

 

Major depressive disorder (MDD), often known as clinical depression, is a mental illness that affects mood, behavior, food, and sleep. The specific origin of MDD is unknown; however, a combination of genes and stress can increase the risk by affecting brain chemistry and reducing the ability to sustain emotional stability. Imbalanced hormones, alcohol or drug misuse, some medical disorders such as cancer or hypothyroidism, and various prescription side effects like as steroids can all contribute to the Major Depressive Disorder (MDD) Treatment Market. Changing lifestyles, such as work stress and alcohol misuse, have resulted in an increase in the prevalence of MDD, which is projected to fuel market expansion throughout the forecast period.

Major Depressive Disorder (MDD) Treatment Market is one of the most common mental disorders in the world, characterized by isolated or recurring major depressive episodes (MDEs). MDD is diagnosed only when an MDE cannot be explained by another psychotic disease, such as schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or another psychotic condition, and there is no history of hypomania or mania. The term unipolar depressive disorder is frequently used to distinguish MDD from bipolar disorder, which includes depressive episodes as well as manic ones. The prevalence of Major Depressive Disorder (MDD) Treatment Market

is expected to rise due to increased awareness, which will lead to accurate diagnosis and, as a result, prompt treatment in primary care settings utilizing antidepressant drugs and/or brief organized psychological therapy. However, significant constraints such as supply-side factors (for example, policies to spend money, resulting in insufficient mental health services, community, and human resources) and demand-side concerns are predicted to stymie expansion (for example, lack of awareness of MDD as a treatable illness, and stigma and social exclusion associated with lower rates of help-seeking).

Key players

Eli Lilly and Company, Allergan, Alkermes, Lundbeck, Johnson & Johnson, Pfizer, Inc., AstraZeneca plc, Merck & Co., GlaxoSmithKline plc, Sanofi S.A., and Takeda Pharmaceutical Company Limited are key participants in the major depressive disorder therapy market.